Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328371 | 0.93 | CDK1 (0.59) | KMT2AMEN1LMNASMN1; SMN2HTT | |
| SCHEMBL23328722 | 0.88 | MEN1 (0.61) | KMT2AMEN1LMNASMN1; SMN2HTT | |
| SCHEMBL23328449 | 0.86 | MEN1 (0.67) | KMT2AMEN1LMNASMN1; SMN2HTT | |
| SCHEMBL23328720 | 0.85 | CDK1 (0.55) | KMT2AMEN1LMNASMN1; SMN2HTT | |
| SCHEMBL23328673 | 0.81 | MEN1 (0.63) | KMT2AMEN1EPHX2TRPV1 | |
| SCHEMBL23328372 | 0.81 | CDK1 (0.67) | KMT2AMEN1LMNASMN1; SMN2HTT | |
| SCHEMBL23328667 | 0.78 | SMN1; SMN2 (0.66) | KMT2AMEN1LMNASMN1; SMN2HTT | |
| SCHEMBL27922870 | 0.77 | MEN1 (0.68) | KMT2AMEN1LMNASMN1; SMN2HTT | |
| SCHEMBL4396949 | 0.77 | KMT2A (0.64) | KMT2AMEN1LMNASMN1; SMN2HTT | |
| SCHEMBL27922871 | 0.77 | CDK1 (0.68) | KMT2AMEN1LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | KENT INNOVATION & ENTERPRISE, UNIVERSITY OF KENT (GB) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | ARF1, ARL1, TLR1 | KMT2A 2533/4885MEN1 1300/4885LMNA 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.